Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Maher

Showing results (1011-1020 of 1,158) with videos related to

Pageof 116
Sort By:
The Lancet. Respiratory Medicine|November 14, 2022
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trialToby M Maher, Veronica A Tudor, Peter Saunders, et al.
Insights Into Imaging|October 25, 2017
Body composition determinants of radiation dose during abdominopelvic CTPatrick D McLaughlin, Liam Chawke, Maria Twomey, et al.
The Lancet. Respiratory Medicine|October 3, 2025
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trialT M Maher, J G Goldin, J Hood, et al.
Biorxiv : the Preprint Server for Biology|June 10, 2024
Association between mosaic loss of chromosome Y and pulmonary fibrosis susceptibility and severityDapeng Wang, Niran Hadad, Samuel Moss, et al.
BMJ Open Respiratory Research|February 11, 2026
Assessment of mosaic loss of chromosome Y in pulmonary fibrosis reveals limited association with susceptibility or disease severityDapeng Wang, Niran Hadad, Samuel Moss, et al.
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled TrialToby M Maher, Mark J Hamblin, Won-Ii Choi, et al.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
Cross-ancestry evaluation of idiopathic pulmonary fibrosis genetic risk variantsRitah Nabunje, Beatriz Guillen-Guio, Tamara Hernandez-Beeftink, et al.
BMJ Open|June 4, 2021
Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility studyClaire M Nolan, Suhani Patel, Ruth E Barker, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
AJNR. American Journal of Neuroradiology|January 8, 2021
Clinical, Imaging, and Lab Correlates of Severe COVID-19 LeukoencephalopathyO Rapalino, A Pourvaziri, M Maher, et al.
Pageof 116

Showing results (1011-1020 of 1,158) with videos related to

Sort By:
Pageof 116
The Lancet. Respiratory Medicine|November 14, 2022
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trialToby M Maher, Veronica A Tudor, Peter Saunders, et al.
Insights Into Imaging|October 25, 2017
Body composition determinants of radiation dose during abdominopelvic CTPatrick D McLaughlin, Liam Chawke, Maria Twomey, et al.
The Lancet. Respiratory Medicine|October 3, 2025
Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trialT M Maher, J G Goldin, J Hood, et al.
Biorxiv : the Preprint Server for Biology|June 10, 2024
Association between mosaic loss of chromosome Y and pulmonary fibrosis susceptibility and severityDapeng Wang, Niran Hadad, Samuel Moss, et al.
BMJ Open Respiratory Research|February 11, 2026
Assessment of mosaic loss of chromosome Y in pulmonary fibrosis reveals limited association with susceptibility or disease severityDapeng Wang, Niran Hadad, Samuel Moss, et al.
American Journal of Respiratory and Critical Care Medicine|May 5, 2026
Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled TrialToby M Maher, Mark J Hamblin, Won-Ii Choi, et al.
Medrxiv : the Preprint Server for Health Sciences|May 4, 2026
Cross-ancestry evaluation of idiopathic pulmonary fibrosis genetic risk variantsRitah Nabunje, Beatriz Guillen-Guio, Tamara Hernandez-Beeftink, et al.
BMJ Open|June 4, 2021
Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility studyClaire M Nolan, Suhani Patel, Ruth E Barker, et al.
The New England Journal of Medicine|May 19, 2025
Nerandomilast in Patients with Idiopathic Pulmonary FibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
AJNR. American Journal of Neuroradiology|January 8, 2021
Clinical, Imaging, and Lab Correlates of Severe COVID-19 LeukoencephalopathyO Rapalino, A Pourvaziri, M Maher, et al.
Pageof 116